• 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • 2021-03
  • br Koseki J Konno M Asai A


    [88] Koseki J, Konno M, Asai A, Colvin H, Kawamoto K, Nishida N, Sakai D, Kudo T, Satoh T, Doki Y, Mori M, Ishii H. Enzymes of the one-carbon folate metabolism as anticancer targets pre-dicted by survival rate analysis. Sci Rep 2018;8:303.
    [89] Hogan LE, Meyer JA, Yang J, Wang J, Wong N, Yang W, Con-dos G, Hunger SP, Raetz E, Saffery R, Relling MV, Bhojwani D, Morrison DJ, Carroll WL. Integrated genomic analysis of re-lapsed childhood acute lymphoblastic leukemia reveals thera-peutic strategies. Blood 2011;118:5218–26.
    [90] Popat S, Matakidou A, Houlston RS. Thymidylate synthase ex-pression and prognosis in colorectal cancer: a systematic re-view and meta-analysis. J Clin Oncol 2004;22:529–36.
    [91] Cong X, Lu C, Huang X, Yang D, Cui X, Cai J, Lv L, He S, Zhang Y, Ni R. Increased expression of glycinamide ribonu-cleotide transformylase is associated with a poor prognosis in hepatocellular carcinoma, and it promotes liver cancer cell pro-liferation. Hum Pathol 2014;45:1370–8.
    [92] Liu X, Ding Z, Liu Y, Zhang J, Liu F, Wang X, He X, Cui G, Wang D. Glycinamide ribonucleotide formyl trans-ferase is frequently overexpressed in glioma and critically regulates the proliferation of glioma cells. Pathol Res Pract 2014;210:256–63.
    [94] Kager L, Cheok M, Yang W, Zaza G, Cheng Q, Panetta JC, Pui CH, Downing JR, Relling MV, Evans WE. Folate path-way gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. J Clin Invest 2005;115:110–17.
    [99] Umene K, Banno K, Kisu I, Yanokura M, Nogami Y, Tsuji K, Masuda K, Ueki A, Kobayashi Y, Yamagami W, Nomura H, Tominaga E, Susumu N, Aoki D. Aurora kinase inhibitors: po-tential molecular-targeted drugs for gynecologic malignant tu-mors. Biomed Rep 2013;1:335–40.
    [100] Wardell SE, Ilkayeva OR, Wieman HL, Frigo DE, Rath-mell JC, Newgard CB, McDonnell DP. Glucose metabolism as a target of histone deacetylase inhibitors. Mol Endocrinol 2009;23:388–401.
    [101] Price RJ, Lillycrop KA, Burdge GC. Folic Geneticin supplementation in vitro induces cell type-specific changes in BRCA1 and BRCA 2 mRNA expression, but does not alter DNA methylation of their promoters or DNA repair. Nutr Res 2015;35:532–44. [102] Matherly LH, Wilson MR, Hou Z. The major facilitative folate transporters solute carrier 19A1 and solute carrier 46A1: biol-ogy and role in antifolate chemotherapy of cancer. Drug Metab Dispos 2014;42:632–49.
    [103] Deghan Manshadi S, Ishiguro L, Sohn KJ, Medline A, Ren-lund R, Croxford R, Kim YI. Folic acid supplementation pro-motes mammary tumor progression in a rat model. PLoS One 2014;9:e84635.
    [104] Chattopadhyay E, Roy B. Altered mitochondrial signalling and metabolism in cancer. Front Oncol 2017;7:43.
    [105] Zhu J, Blenis J, Yuan J. Activation of PI3K/Akt and MAPK path-ways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1. Proc Natl Acad Sci U S A 2008;105:6584–9.  D.-J. Min, S. Vural and J. Krushkal
    [107] Kilic-Eren M, Boylu T, Tabor V. Targeting PI3K/Akt represses Hypoxia inducible factor-1α activation and sensitizes Rhab-domyosarcoma and Ewing’s sarcoma cells for apoptosis. Can-cer Cell Int 2013;13:36.
    [110] Swords RT, Schenk T, Stengel S, Gil VS, Petrie KR, Perez A, Ana R, Watts JM, Vargas F, Elias R, Zelent A. Inhibition of the PI3K/AKT/mTOR pathway leads to down-regulation of c-Myc and overcomes resistance to ATRA in acute myeloid leukemia. Blood 2015;126:1363.
    [111] Emerling BM, Platanias LC, Black E, Nebreda AR, Davis RJ, Chandel NS. Mitochondrial reactive oxygen species activation of p38 mitogen-activated protein kinase is required for hypoxia signaling. Mol Cell Biol 2005;25:4853–62.
    Ca2+/calmodulin kinase-dependent activation of hypoxia in-ducible factor 1 transcriptional activity in cells subjected to in-termittent hypoxia. J Biol Chem 2005;280:4321–8.
    [114] Laemmle A, Lechleiter A, Roh V, Schwarz C, Portmann S, Furer C, Keogh A, Tschan MP, Candinas D, Vorburger SA, Stroka D. Inhibition of SIRT1 impairs the accumulation and tran-scriptional activity of HIF-1α protein under hypoxic conditions. PLoS One 2012;7:e33433.
    [115] Zwaans BM, Lombard DB. Interplay between sirtuins, MYC and hypoxia-inducible factor in cancer-associated metabolic repro-gramming. Dis Model Mech 2014;7:1023–32.
    [118] Woo CC, Chen WC, Teo XQ, Radda GK, Lee PT. Downregu-lating serine hydroxymethyltransferase 2 (SHMT2) suppresses tumorigenesis in human hepatocellular carcinoma. Oncotarget 2016;7:53005–17.
    [119] Grarup N, Sulem P, Sandholt CH, Thorleifsson G, Ahluwalia TS, Steinthorsdottir V, Bjarnason H, Gudbjarts-son DF, Magnusson OT, Sparso T, Albrechtsen A, Kong A, Masson G, Tian G, Cao H, Nie C, Kristiansen K, Husemoen LL, Thuesen B, Li Y, Nielsen R, Linneberg A, Olafsson I, Eyjolfs-son GI, Jorgensen T, Wang J, Hansen T, Thorsteinsdottir U, Stefansson K, Pedersen O. Genetic architecture of vitamin B12 and folate levels uncovered applying deeply sequenced large datasets. PLoS Genet 2013;9:e1003530.